

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Boughton-Smith	Art Unit	: Unknown
Serial No.	: 10/558,354	Examiner	: Unknown
Filed	: August 24, 2006	Conf. No.	: 5761
Title	: A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR ALPHA		

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request. This is the second of two separate information disclosure statements which are being filed today. The reason for the separate filings is due to the limited number of attachments per filing.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: \_\_\_\_\_

*April 9, 2008*

  
\_\_\_\_\_  
John T. Kendall, Ph.D.

Reg. No. 50,680

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

21897698.doc

**CERTIFICATE OF MAILING BY EFS-WEB FILING**

I hereby certify that this paper was filed with the Patent and Trademark Office using the EFS-WEB system on this date: April 9, 2008